Efferon Raises €4.3 Million to Expand Devices
The biotech company plans to take its hemoadsorption devices into Europe, India, and Latin America following the funding round.
Updated on Nov. 10, 2026 in Healthcare
Efferon, a biotech company developing hemoadsorption devices, raised €4.3 million from existing private investors in the DACH region. The funding will support commercial expansion of its Efferon LPS and Efferon NEO products in Europe, India, and Latin America.
Why it matters
The devices remove endotoxins and excessive inflammatory mediators from the bloodstream, and the company says its technology is already approved and used across Europe. The round is positioned to strengthen its distributor network, regulatory work, and clinical evidence base.
Efferon reported revenue above €1.1 million in 2025 and expects intensive care product revenue to reach roughly €5 million in 2027. Outpatient products could add up to €3 million more, but only if registration succeeds.
The players
Efferon
A biotech company developing hemoadsorption devices that remove endotoxins and inflammatory mediators from the bloodstream, with products approved and used across Europe.
The details
The €4.3 million came from existing private investors in the DACH region. Management says the capital will fund the expansion of its distributor network, regulatory work, and clinical evidence base, and is expected to lay the groundwork for a full Series A round.
Timeline
2025: Efferon revenue exceeded €1.1 million.
2027: Projected intensive care product revenue reaches approximately €5 million.
Market Landscape
Efferon's expansion into India and Latin America extends hemoadsorption, an extracorporeal blood-purification approach, beyond its current European approval base. The move positions the company to compete for distribution in regions where the therapy is not yet widely established.
For patients in treatment settings where hemoadsorption is used, expanded availability could eventually broaden access to the therapy. The projections are company estimates, and rollout timing in new markets has not been specified.
The takeaway
Growth in specialized medical devices often depends as much on regulatory registration and distributor reach as on the technology itself. Watching whether Efferon's outpatient product approvals proceed will show how far its revenue projections can hold.
Further reading
Explore more Healthcare coverage for context on how medical device companies are scaling abroad.
Source note: This article includes information reported by Tech.
